Skip to main content
. 2015 Aug 6;133(2):124–130. doi: 10.1111/ane.12467

Figure 2.

Figure 2

Median percent change from baseline 28‐day seizure frequency over time during open‐label Oxtellar XR (SPN‐804) treatment (A) and patients with ≥ 50% reduction from baseline seizure frequency (B). ITT population; last observation carried forward.